Table 1. Summary of IC50 in the Alamar Blue viability assay readout for eight resupplied agonists and 13 antagonists toward the Y79 and RB355 human retinoblastoma cell lines.
Alamar Blue viability assay IC50 (µM) | ||||||||
Y79 | RB355 | |||||||
Compound name | Biological activity | 0 µM resv. | 30 µMresv. | 80 µMresv. | 0 µMresv. | 30 µMresv. | 80 µMresv. | |
Agonist | Berberine chloride | Antibiotic | 24* | 15 | 8.6 | 59* | 23 | 6.8 |
Perphenazine | Antipsychotic | 32 | 27 | 16 | 25 | 19 | 9.8 | |
Avermectin B1 | Antiparasitic | >100* | >100 | >100 | 55* | 47* | 60* | |
Phorbol 12-myristate 13 acetate | PKC activator | >100 | >100 | >100* | >100 | >100 | 67* | |
Budesonide | Steroid | >100 | >100 | >100* | >100 | >100 | >100* | |
Piperazine carbazole ethanol derivative | Cyto C release inhibitor | 9.2 | 7.9 | 7.4 | 12 | 8.7 | 7.0 | |
Triamterene | Diuretic | >100* | >100* | >100* | 33* | >100* | >100* | |
Lercanidipine | Ion channel inhibitor | 38* | 36* | 38* | 19 | 57* | 33* | |
Antagonist | Nocodazole | Microtubule inhibitor | 34* | 21* | 5.6* | 1.1 | 0.53* | >100* |
Chelidonine | Microtubule inhibitor | 6.8* | 7.9* | 4.9* | 1.6 | 1.3* | >100* | |
Albendazole | Microtubule inhibitor | >100* | >100* | >100* | 20* | 23* | >100* | |
ZM 447439 | Aurora B kinase inhibitor | 25* | 6.3* | 4.1* | 1.4 | 1.4 | 8.4 | |
Tolperisone | Ion channel inhibitor | 74* | 67* | 35* | >100* | 73* | 49* | |
PALDA | Ion channel inhibitor | 5.2 | 13 | 10 | 6.1 | 15 | 15 | |
SKF 96365 | Ion channel inhibitor | >100* | 51* | 58* | 8.1 | 9.5 | 82* | |
Floxuridine | Antimetabolite | 0.44 | 0.43 | 0.45 | 0.82 | 0.76 | 1.4 | |
Thioguanosine | Antimetabolite | 1.04 | 1.03 | 0.79 | 1.4 | 1.1 | 0.78 | |
Quinidine | NA+ K+ ATPase inhibitor | >100 | >100 | >100* | 74* | >100 | 61* | |
LY 171883 | LTD4 antagonist | >100 | >100 | >100 | >100 | >100 | >100 | |
Caffeic acid phenethyl ester | NFKB inhibitor | >100* | >100* | 75* | 21* | 49* | 36* | |
IKK 16 | IKK 16 inhibitor | 3.6 | 4.8 | 6.1 | 5.9 | 6.5 | 6.6 |